Enbezotinib

N/A

Report date: 2023/06/19 20:00:35
NME

Base Information

Drug NameEnbezotinib
Drug Alias NameTPX-0046
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase SRC inhibitorsTyrosine-protein kinase receptor RET inhibitors
TargetsTyrosine-protein kinase SRCTyrosine-protein kinase receptor RET
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Solid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTurning Point Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTurning Point Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsMedullary thyroid cancer (MTC)Solid tumoursCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A